KYTX stock touches 52-week low at $2.78 amid sharp annual decline
Kyverna Therapeutics Inc. (KYTX) stock has reached a new 52-week low, trading at $2.78, down 10.4% in the past week alone, as the biotechnology firm faces a challenging market environment. According ...
FDA approves new genetic disorder drug
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
Tivic Health acquires exclusive rights to Entolimod from Statera BioPharma
Tivic Health (TIVC) announced it has acquired worldwide exclusive license rights from Statera Biopharma (STAB) to the late-stage Toll-like ...
Wall Street Journal20h
Summit Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
MyChesCo on MSN22h
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...